Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939111 | 0.96 | SLC6A2 (0.41) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4059102 | 0.91 | TRPV4 (0.40) | SLC6A2TRPV4SLC6A4GBA1METAP2 | |
| SCHEMBL4945111 | 0.90 | SLC6A2 (0.41) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4937965 | 0.90 | SLC6A2 (0.41) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4939108 | 0.87 | TRPV4 (0.40) | SLC6A2TRPV4SLC6A4GBA1METAP2 | |
| SCHEMBL4943918 | 0.86 | SLC6A2 (0.41) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4945948 | 0.86 | SLC6A2 (0.41) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4945270 | 0.83 | SLC6A2 (0.39) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4943811 | 0.81 | SLC6A2 (0.39) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4940924 | 0.80 | SLC6A2 (0.39) | SLC6A2TRPV4SLC6A3SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885TRPV4 1234/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.